Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Vivesto AB ( (SE:VIVE) ) has shared an update.
Vivesto AB has completed a fully subscribed rights issue, raising approximately SEK 53.8 million before costs at a subscription price of SEK 0.10 per share, with about 62.1 percent of the offering taken up through subscription rights, 1.9 percent without rights, and the remaining 36.0 percent covered by guarantee undertakings from existing shareholders and external investors, including a significant contribution from major shareholder Arwidsro Investment AB. The capital increase doubles the company’s share count to 1,076,086,910 shares, implying a 50 percent dilution for non-participating shareholders, with a potential additional 5.4 percent dilution from a planned compensation issue to guarantors, while trading in the newly issued shares on Nasdaq Stockholm is expected around mid-February 2026, strengthening Vivesto’s balance sheet and providing funding capacity albeit at the cost of substantial dilution.
More about Vivesto AB
Vivesto AB is a Sweden-based pharmaceutical company listed on Nasdaq Stockholm, focusing on the development and commercialization of cancer therapies and other specialty pharmaceuticals for international markets.
Average Trading Volume: 1,413,148
Technical Sentiment Signal: Sell
Current Market Cap: SEK109.5M
For an in-depth examination of VIVE stock, go to TipRanks’ Overview page.